Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1082554 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $524.70Day +0.20%Mkt cap $22.3BP/E (FY) 18.8×1Y +76.3%Off 52W high −13.9%Vol (1Y) 47.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.9% of sh out |
| Days to cover5.5d |
| 13F net flow (QoQ)−0.50% |
| Top-10 13F concentration50.2% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)18.8× |
| Sales (TTM)$3.17B |
| Earnings (TTM)$1.29B |
| ROE19.7% |
| Net margin41.9% |
| ROIC22.6% |
| EPS growth 3Y22.9% |
| Sales growth 3Y18.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+7.7% |
| 1Y+76.3% |
| 3Y+116.2% |
| 5Y+184.8% |
| 10Y+333.6% |
| Since incept. (ann.)+15.2% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)47.7% |
| Ann. volatility (3Y)37.0% |
| Sharpe (1Y)1.42 |
| Sharpe (3Y)0.87 |
| Max drawdown (1Y)−12.3% |
| Max drawdown (3Y)−33.0% |
| Beta (3Y vs SPY)0.28 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 5.4M | $3.2B | 12.72% | +4.4% |
| Avoro Capital Advisors LLC | 2.6M | $1.6B | 6.20% | +0.9% |
| WELLINGTON MANAGEMENT GROUP LLP | 2.3M | $1.3B | 5.33% | −7.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $1.2B | 4.72% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $1.2B | 4.61% | new |
| STATE STREET CORP | 1.8M | $1.1B | 4.34% | +0.1% |
| RENAISSANCE TECHNOLOGIES LLC | 1.8M | $1.1B | 4.21% | −6.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2M | $730M | 2.90% | +3.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $5.82 | −12.2% | $781.5M | −1.6% |
| 2025-12-31 | 2026-02-25 | — | — | $790.2M | +7.4% |
| 2025-09-30 | 2025-10-29 | $7.16 | +12.1% | $799.5M | +6.8% |
| 2025-06-30 | 2025-07-30 | $6.41 | +9.6% | $798.6M | +11.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 95% · Non Us 5%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
